Cytokine Modulation in Experimental Endotoxemia: Characterization of an ex vivo Whole Blood Model
- 1 April 2000
- journal article
- research article
- Published by S. Karger AG in European Surgical Research
- Vol. 32 (2) , 65-73
- https://doi.org/10.1159/000008743
Abstract
A new model was developed to study cytokine regulation and modulation in whole blood ex vivo. The model is characterized by stable leukocyte counts and high leukocyte viability throughout the experimental period. Oxygen consumption per time decreased slowly, whereas carbon dioxide partial pressure increased accordingly throughout the experiment. In this model, the anti-inflammatory effects of recombinant human (rh) interleukin (IL)-4, rhIL-10 and rhIL-13 on lipopolysaccharide (LPS) stimulated (10 ng/ml) leukocytes were examined and compared by measuring their ability to inhibit the release and mRNA levels of tumor necrosis factor (TNF)α, IL-6 and IL-1β. rhIL-10 potently inhibited the release of TNF-α, IL-6 and IL-1β in a potent and dose-dependent manner, but did not influence the mRNA levels of these cytokines in CD14-positive cells. Also, rhIL-4 and rhIL-13 inhibited the release of IL-6 and IL-1β in a potent and dose-dependent manner, however, stronger maximal inhibition of IL-1β (85%) than of IL-6 (60%) was obtained. In contrast, rhIL-4 and rhIL-13 seemed to have both stimulatory and inhibitory effects on plasma values of TNF-α. The effects of 10 ng/ml LPS showed to be signalling through the CD14 receptor, since blood treated with a monoclonal anti-CD14 antibody did not produce any TNF-α. The whole blood model described in this study is in our opinion a useful tool for investigating immunomodulating effects on a mixed white blood cell population.Keywords
This publication has 10 references indexed in Scilit:
- The Cytokines IL-1ß and IL-1 Receptor Antagonist, IL-2 and IL-2 Soluble Receptor-a, IL-6 and IL-6 Soluble Receptor, TNF-a and TNF Soluble Receptor I, and IL10 in Drained and Systemic Blood after Major Orthopaedic SurgeryBritish Journal of Surgery, 1999
- Interleukin-4 and -13 Inhibit Tumor Necrosis Factor-α mRNA Translational Activation in Lipopolysaccharide-induced Mouse MacrophagesJournal of Biological Chemistry, 1997
- Complement activation during storage of whole blood, red cells, plasma, and buffy coatTransfusion, 1997
- CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide.The Journal of Experimental Medicine, 1995
- Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production.The Journal of Experimental Medicine, 1995
- Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL‐6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL‐6 levels and febrile transfusion reactionsTransfusion, 1993
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cellsCytokine, 1991
- The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.The Journal of Experimental Medicine, 1989
- A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytesJournal of Immunological Methods, 1986